Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Cellectar Biosciences announced an oversubscribed financing of up to $140 million, led by Nantahala Capital, to fund the confirmatory study and NDA filing for Iopofosine I 131 in Waldenström Macroglobulinemia. The transaction consists of approximately $35 million in upfront proceeds and $105 million in milestone-based securities, with participation from institutional investors including Balyasny Asset Management and Janus Henderson Investors.
Key figures
- Deal Value Usd
- 140000000
- Upfront proceeds
- $35 million
- Milestone securities
- $105 million
- Warrant exercise price investors
- $2.65
- Warrant exercise price management
- $2.88
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.